Vaxcyte (PCVX) Payables (2019 - 2026)
Vaxcyte (PCVX) posted quarterly Payables of $63.1 million for Q1 2026, up 207.4% year-over-year from $20.5 million in Q1 2025, and down 11.06% quarter-over-quarter from $70.9 million in Q4 2025.
Vaxcyte (PCVX) Payables (2019 - 2026) Analysis & Trends
Vaxcyte (PCVX) has reported Payables for 8 consecutive years, with $63.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Payables rose 207.4% year-over-year to $63.1 million; the TTM figure through Mar 2026 stood at $63.1 million (up 207.4% YoY), while the FY2025 annual figure was $70.9 million, up 46.34% from the prior year.
- Payables slipped to $63.1 million in Q1 2026 per PCVX's latest filing, from $70.9 million in the prior quarter.
- Across five years, Payables topped out at $70.9 million in Q4 2025 and bottomed at $4.8 million in Q1 2022.
- Historically, Payables has averaged $24.6 million across 5 years, with a median of $16.3 million in 2023.
- Annual changes were most pronounced in 2022 — Payables tumbled 84.93% — and 2024, when it jumped 232.16%.
- Vaxcyte's Payables stood at $9.8 million in 2022, then surged by 48.92% to $14.6 million in 2023, then surged by 232.16% to $48.5 million in 2024, then jumped by 46.34% to $70.9 million in 2025, then fell by 11.06% to $63.1 million in 2026.
- Business Quant data shows PCVX's Payables at $63.1 million in Q1 2026, $70.9 million in Q4 2025, and $49.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Vaxcyte | 8.41 Bn | 8.41 Bn | - | 100.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 100.92 Mn |
| Mar 31, 2026 | 63.06 Mn |
| Dec 31, 2025 | 70.90 Mn |
| Sep 30, 2025 | 48.96 Mn |
| Jun 30, 2025 | 31.41 Mn |
| Mar 31, 2025 | 20.51 Mn |
| Dec 31, 2024 | 48.45 Mn |
| Sep 30, 2024 | 18.22 Mn |
| Jun 30, 2024 | 10.47 Mn |
| Mar 31, 2024 | 21.72 Mn |
| Dec 31, 2023 | 14.59 Mn |
| Sep 30, 2023 | 15.70 Mn |
| Jun 30, 2023 | 16.27 Mn |
| Mar 31, 2023 | 11.62 Mn |
| Dec 31, 2022 | 9.80 Mn |
| Sep 30, 2022 | 5.49 Mn |
| Jun 30, 2022 | 7.04 Mn |
| Mar 31, 2022 | 4.80 Mn |
| Dec 31, 2021 | 6.76 Mn |
| Sep 30, 2021 | 25.71 Mn |